| Literature DB >> 27656403 |
Hassan Mziaut1, Bernard Mulligan1, Peter Hoboth1, Oliver Otto2, Anna Ivanova1, Maik Herbig2, Desiree Schumann3, Tobias Hildebrandt3, Jaber Dehghany4, Anke Sönmez1, Carla Münster1, Michael Meyer-Hermann4, Jochen Guck2, Yannis Kalaidzidis5, Michele Solimena6.
Abstract
OBJECTIVE: Insulin release from pancreatic islet β cells should be tightly controlled to avoid hypoglycemia and insulin resistance. The cortical actin cytoskeleton is a gate for regulated exocytosis of insulin secretory granules (SGs) by restricting their mobility and access to the plasma membrane. Prior studies suggest that SGs interact with F-actin through their transmembrane cargo islet cell autoantigen 512 (Ica512) (also known as islet antigen 2/Ptprn). Here we investigated how Ica512 modulates SG trafficking and exocytosis.Entities:
Keywords: D, diffusion coefficient; EGFP, enhanced green fluorescent protein; F-actin; Granules; IPGTT, intraperitoneal glucose tolerance test; IVGTT, intravenous glucose tolerance test; Ica512; Ica512, islet cell autoantigen; Insulin; OGTT, oral glucose tolerance test; RT-DC, real-time deformability cytometry; SE, standard error; SG, secretory granules; Secretion; TIRFM, total internal reflection fluorescence microscopy; Villin
Year: 2016 PMID: 27656403 PMCID: PMC5021679 DOI: 10.1016/j.molmet.2016.05.015
Source DB: PubMed Journal: Mol Metab ISSN: 2212-8778 Impact factor: 7.422
Transcriptomic profiling of mouse islets from Ica512−/− and control littermates.
| Gene name | Probe ID | Illumina | Agilent | RNA sequencing | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Log2 fold change | p-val | Adj p-val | Log2 fold change | p-val | Adj p-val | Log2 fold change | p-val | Adj p-val | ||
| ILMN_1245627 | −2.98 | 3.20E−06 | 2.30E−02 | −2.19 | 0.0000 | 0.0000 | −4.36 | 4.16E−119 | 9.40E−115 | |
| ILMN_2518406 | −1.04 | 1.90E−05 | 6.20E−02 | −1.32 | 0.0000 | 0.0000 | −0.66 | 8.27E−05 | 0.05 | |
Figure 1Villin expression is reduced in mice and Confocal images of mouse pancreatic cryosections from Ica512+/+ and Ica512−/− mice were co-stained for villin (red) and insulin (green). The nuclei were stained with DAPI (blue). (B) Immunoblotting for Ica512, villin, and γ-tubulin using extracts of islets isolated from Ica512+/+ or Ica512−/− mice (in triplicate). (C) Immunoblotting for Ica512, villin, and γ-tubulin using extracts of control and Ica512-depleted MIN6 cells (in triplicate).
Figure 2Glucose tolerance and insulin sensitivity of mice. (A) Immunoblotting for villin and γ-tubulin using extracts of islets isolated from villin and villin mice. (B,C) Intraperitoneal (B) and intravenous (C) glucose tolerance tests in 40–44-week-old villin and villin mice. (D) Body weight of 44-week-old villin and villin mice. (E) Insulin tolerance tests in 44-week-old villin and villin mice.
Figure 3Deformability of islets. (A) Deformability of mouse islets treated with or without latrunculin A (200 nM). (B) Deformation of villin and villin islets in the reservoir. (C) Images of single villin and villin islet cells in the reservoir or in the constricted channel of the microfluidic chamber. (D) Scatterplot of villin and villin islet cell deformation versus cell size. Contour lines representing 95% and 50% of the maximum cell density are shown as solid and dashed lines, respectively. The size distribution and deformability distribution are shown in the top and right panels, respectively, in A, B, and D.
Figure 4Insulin secretion is decreased in islets and . (A) Insulin stimulation index of villin and villin islets. (B) Immunoblots for villin and γ-tubulin in extracts of villin islets treated with control or villin siRNA oligonucleotides. (C) Insulin stimulation index of villin and villin islets treated with control or villin siRNA oligonucleotides. (D–F) Insulin content at 2.8 and 25 mM glucose (D), stimulation index (E), and insulin-1 mRNA expression (F) of control or villin-depleted MIN6 cells. (G) Basal and glucose-stimulated insulin secretion in villin islets treated with control or villin siRNA oligonucleotides. (H) Immunoblotting for GFP and γ-tubulin in extracts of MIN6 cells transfected with GFP or villin-GFP and treated with control or villin siRNA oligonucleotides. (I) Insulin stimulation index of MIN6 cells transfected with GFP or villin-GFP and treated with control or villin siRNA oligonucleotides.
Figure 5SG dynamics in Density of SGs in resting or glucose-stimulated MIN6 cells transfected with GFP or villin-GFP and treated with control or villin siRNA oligonucleotides. (B–D) Mean speed of processive SGs (B), collective diffusion coefficient (C), and mean square displacement of SGs (D) in resting or glucose-stimulated MIN6 cells transfected with GFP and treated with control or villin siRNA oligonucleotides. (E,F) Deconvolution in three dynamic components of the mean square displacement of SGs in resting (E) or glucose-stimulated (F) MIN6 cells transfected with GFP and treated with control or villin siRNA oligonucleotides. Highly dynamic SGs: red line; restricted SGs: green line; nearly immobile SGs: blue line. (G–I) Percentage of highly dynamic (G), restricted (H), and nearly immobile (I) SGs relative to the total number of tracked SGs in resting or glucose-stimulated MIN6 cells transfected with GFP and treated with control or villin siRNA oligonucleotides.
Figure 6Altered actin cage size in Actin cage size (A) and insulin stimulation index (B) in resting or glucose-stimulated MIN6 cells transfected with GFP or villin-GFP and treated with either control, villin, or Ica512 siRNA oligonucleotides. (C) Remodeling of SG cages in villin and villin-depleted cells.